Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database

[1]  E. Vittinghoff,et al.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[2]  Ailsa E Gebbie,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288(3): 321-333 , 2002, Journal of Family Planning and Reproductive Health Care.

[3]  C. Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[4]  Stephen B. Hulley,et al.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy : Heart and Estrogen/Progestin Study fellow-up (HERS II) , 2002 .

[5]  X. Marchandise,et al.  Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy. , 2001, Joint, bone, spine : revue du rhumatisme.

[6]  B. Ettinger,et al.  Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen , 2001, Menopause.

[7]  B. Ettinger.  Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation. , 2000, Menopause.

[8]  S. Adami,et al.  Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis. , 2000, Bone.

[9]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[10]  A. Haboubi,et al.  Osteoporosis management: physicians' recommendations and womens' compliance following osteoporosis testing. , 1999, Women & health.

[11]  D. Felsenberg,et al.  Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study , 1999, Osteoporosis International.

[12]  K. Lutfey,et al.  Beyond "compliance" is "adherence". Improving the prospect of diabetes care. , 1999, Diabetes care.

[13]  P. Sarrel.  Improving adherence to hormone replacement therapy with effective patient-physician communication. , 1999, American journal of obstetrics and gynecology.

[14]  P. Vestergaard,et al.  Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. , 1997, Maturitas.

[15]  A. Cano,et al.  Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. , 1994, Maturitas.

[16]  G. Blake,et al.  Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis , 1992, British journal of obstetrics and gynaecology.

[17]  W. Mysiw,et al.  Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[18]  V. Ravnikar.  Compliance with hormone therapy. , 1987, American journal of obstetrics and gynecology.

[19]  Peter P. Morgan,et al.  Compliance in Health Care , 1979 .

[20]  I M Rosenstock,et al.  Patients' compliance with health regimens. , 1975, JAMA.

[21]  F. Ayd.  Single Daily Dose of Antidepressants , 1974 .

[22]  Ayd Fj.  Editorial: Single daily dose of antidepressants. , 1974 .

[23]  A. Porter.  Drug Defaulting in a General Practice* , 1969, British medical journal.

[24]  D. Hosking,et al.  A Comparison of Continuous Alendronate, Cyclical Alendronate and Cyclical Etidronate with Calcitriol in the Treatment of Postmenopausal Vertebral Osteoporosis: A Randomized Controlled Trial , 2000, Osteoporosis International.

[25]  M. Cedars,et al.  A medication use evaluation of alendronate: compliance with administration guidelines. , 1999, Pharmacy practice management quarterly.

[26]  B. Ettinger,et al.  Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. , 1999, Menopause.

[27]  F. Figueras,et al.  Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation. , 1999, Menopause.

[28]  B. Karakoç,et al.  Compliance Considerations with Hormone Replacement Therapy , 1998, Menopause.

[29]  D. Hosking,et al.  Colles' Fracture of the Wrist as an Indicator of Underlying Osteoporosis in Postmenopausal Women: A Prospective Study of Bone Mineral Density and Bone Turnover Rate , 1998, Osteoporosis International.

[30]  M. Dören,et al.  The impact of different HRT regimens on compliance. , 1996, International journal of fertility and menopausal studies.